A unique pipeline database system mapping drug names & index terms.

With Pipeline Data Integrator, you can:

• Undertake powerful cross-data searches. With the drug name & synonym mapping between the different datasets, you can perform a single, comprehensive search which takes into account variations in the drug reports. Thomson Reuters has developed a unique process of mapping the drug names and synonyms from all the pipeline databases, including records that are still classed as research projects or in the early stage development.
• Ensure your searches are complete. The index terms from the different pipeline databases are mapped together, ensuring that all relevant information is captured when performing a search. This means a user can search using terms they are familiar with and retrieve relevant information from all available database sources.
• Save, Annotate and Share Reports. You can view your results as a consolidated report showing all the unique fields from the different data sources; you can add comments to a set of consolidated reports; you can further email these reports and any set of exported reports to colleagues or teams. All searches can be saved, refined, set up as alerts.
• Keep up to date with changes in drug status. You can preference to be kept up to date when major updates occur on specific drugs. A major update would be: phase of development change; new company; new indication or drug name change. Search strategies can be saved and turned into alerts – with results being shown on a daily, weekly or monthly basis.
• Analyze and customize reports. Search results can be refined, filtered and analyzed directly in the PDI system. Custom report templates can be created and saved for future use.

Why choose Pipeline Data Integrator?

• Strategic and planning: Facilitates robust pipeline performance analysis.
• Competitive intelligence: Comprehensive view of all competitive activity. Earliest warning of new developments.
• Information professionals: Rapid completion of in-depth pipeline and corporate research.